Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Attovia Therapeutics, Inc.ATTO · Entity 4984 | Director | August 04, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Attovia Therapeutics, Inc.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-08-03 | Direct | 27,000 |
Reported balance
After 2026-08-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-04 · Grant · Acquired 27,000 · Balance 27,000 F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALPINE IMMUNE SCIENCES, INC.
Report date May 18, 2024 · Filed May 21, 2024
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectAlpine ImmunoSciences, L.P. | 0 |
Reported balance
After 2024-05-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-05-18 · Other · Disposed 2,627,157 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F4: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 96,000 |
Reported balance
After 2024-05-20 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-05-20 · Disposition to issuer · Disposed 13,245 · Balance 96,000 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F5: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-05-20 · Disposition to issuer · Disposed 96,000 · Balance 0 F5: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.31 · Expires 2028-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-20 · Disposition to issuer · Disposed 70,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2027-03-13 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-20 · Disposition to issuer · Disposed 247,951 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2027-04-11 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-05-20 · Disposition to issuer · Disposed 208,916 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.51 · Expires 2029-02-05 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-20 · Disposition to issuer · Disposed 200,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2030-01-22 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-05-20 · Disposition to issuer · Disposed 270,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2031-01-04 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-05-20 · Disposition to issuer · Disposed 255,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F11: One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2032-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-05-20 · Disposition to issuer · Disposed 215,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F12: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.55 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-05-20 · Disposition to issuer · Disposed 336,755 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F13: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.33 · Expires 2034-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-05-20 · Disposition to issuer · Disposed 240,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F14: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.
F3: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
F4: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F5: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date.
F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration.
F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.
F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.
F11: One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F12: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F13: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
F14: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 6, 2026 21:17 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001242882-26-000004 · form4-08062026_090835.xml · derivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2036-08-03 F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 240,000 | Not disclosed Strike: $18.33 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 12 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires 2034-01-03 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F14 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 336,755 | Not disclosed Strike: $7.55 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 11 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 336,755 shares Expires 2033-01-03 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F13 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 215,000 | Not disclosed Strike: $13.30 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 10 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 215,000 shares Expires 2032-01-03 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F12 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 255,000 | Not disclosed Strike: $13.20 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 9 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 255,000 shares Expires 2031-01-04 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F11 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 270,000 | Not disclosed Strike: $3.23 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 8 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 270,000 shares Expires 2030-01-22 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 200,000 | Not disclosed Strike: $6.51 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 7 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2029-02-05 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 208,916 | Not disclosed Strike: $5.02 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 6 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 208,916 shares Expires 2027-04-11 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 247,951 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 5 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 247,951 shares Expires 2027-03-13 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 70,000 | Not disclosed Strike: $11.31 | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · derivative · entry 4 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2028-01-01 F7 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10 · price: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerCommon Stock | 96,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · nonDerivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · shares: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F6 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerCommon Stock | 13,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F5 · balance_after: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. Read SEC document |
| May 18, 2024 Filed May 21, 2024 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 2,627,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001626199-24-000092 · wk-form4_1716249879.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Alpine ImmunoSciences, L.P. Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3 · ownership.direct: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F3 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 08, 2024 Filed May 10, 2024 23:24 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 13,245 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001626199-24-000073 · wk-form4_1715383433.xml · derivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,755 Underlying: Common Stock · 13,245 shares Expires 2033-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| May 08, 2024 Filed May 10, 2024 23:24 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 13,245 | $7.55 | $99,999.75 |
DisclosureSEC source: 0001626199-24-000073 · wk-form4_1715383433.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 23:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 240,000 | $0.00 Strike: $18.33 | $0.00 |
DisclosureSEC source: 0001626199-24-000025 · wk-form4_1704496113.xml · derivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2034-01-03 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 23:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantCommon Stock | 96,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001626199-24-000025 · wk-form4_1704496113.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 F1 · price: Received grant of restricted stock units ("RSUs") for no consideration. One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025 July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| December 28, 2023 Filed Dec 30, 2023 00:32 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionWarrant (right to buy) · Derivative | 74,441 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001626199-23-000149 · wk-form4_1703896326.xml · derivative · entry 6 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Alpine ImmunoSciences, L.P. Disclosed balance after: 0 Underlying: Common Stock · 74,441 shares Expires 2024-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Pursuant to the terms of a Securities Purchase Agreement, dated January 15, 2019 by and among the Issuer and the Purchasers set forth on the signature pages thereto, holder purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock. F3 · ownership.direct: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F3 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 28, 2023 Filed Dec 30, 2023 00:32 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 1,016 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001626199-23-000149 · wk-form4_1703896326.xml · derivative · entry 5 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,951 Underlying: Common Stock · 1,016 shares Expires 2027-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this line were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F7 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 20, 2021. Read SEC document |
| December 28, 2023 Filed Dec 30, 2023 00:32 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Tax withholdingCommon Stock | 48,264 | $19.65 | $948,387.60 |
DisclosureSEC source: 0001626199-23-000149 · wk-form4_1703896326.xml · nonDerivative · entry 4 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Alpine ImmunoSciences, L.P. Disclosed balance after: 2,627,157 F5 · kind: On December 28, 2023, the warrant reported herein was net exercised in full for $12.74 per share, resulting in Issuer's withholding of 48,264 shares to pay the exercise price and issuing to the reporting person the remaining 26,177 shares F6 · price: Represents the average closing price of Issuer's common stock for the five consecutive trading days ending on December 27, 2023 (the date immediately preceding the warrant exercise date). F3 · ownership.direct: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F3 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 28, 2023 Filed Dec 30, 2023 00:32 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 74,441 | $12.74 | $948,378.34 |
DisclosureSEC source: 0001626199-23-000149 · wk-form4_1703896326.xml · nonDerivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Alpine ImmunoSciences, L.P. Disclosed balance after: 2,675,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F3 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 28, 2023 Filed Dec 30, 2023 00:32 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 1,016 | $20.04 | $20,361.96 |
DisclosureSEC source: 0001626199-23-000149 · wk-form4_1703896326.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this line were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 28, 2023 Filed Dec 30, 2023 00:32 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 1,016 | $0.65 | $660.40 |
DisclosureSEC source: 0001626199-23-000149 · wk-form4_1703896326.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this line were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 29,573 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · derivative · entry 12 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,967 Underlying: Common Stock · 29,573 shares Expires 2027-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F8 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 20, 2021. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 29,573 | $20.04 | $592,716.85 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · nonDerivative · entry 7 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.37. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 29,573 | $0.65 | $19,222.45 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · nonDerivative · entry 6 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 22,084 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · derivative · entry 11 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,540 Underlying: Common Stock · 22,084 shares Expires 2027-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F8 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 20, 2021. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 2,402 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · derivative · entry 10 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,402 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F7 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 16, 2019. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 24,486 | $20.22 | $495,217.11 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · nonDerivative · entry 5 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 22,084 | $0.65 | $14,354.60 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · nonDerivative · entry 4 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 2,402 | $0.45 | $1,080.90 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · nonDerivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. Read SEC document |
| December 22, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 37,825 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · derivative · entry 9 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,402 Underlying: Common Stock · 37,825 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F7 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 16, 2019. Read SEC document |
| December 22, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 37,825 | $20.43 | $772,594.54 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.87. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 22, 2023 Filed Dec 28, 2023 02:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 37,825 | $0.45 | $17,021.25 |
DisclosureSEC source: 0001626199-23-000147 · wk-form4_1703729261.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 00:34 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 2,402 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001626199-23-000144 · wk-form4_1703205253.xml · derivative · entry 4 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,227 Underlying: Common Stock · 2,402 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F5 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 16, 2019. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 00:34 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 2,402 | $20.01 | $48,063.78 |
DisclosureSEC source: 0001626199-23-000144 · wk-form4_1703205253.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 00:34 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 2,402 | $0.45 | $1,080.90 |
DisclosureSEC source: 0001626199-23-000144 · wk-form4_1703205253.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on March 30, 2023. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 02:02 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionStock Option (Right to buy) · Derivative | 8,613 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001626199-23-000134 · wk-form4_1702432945.xml · derivative · entry 7 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,629 Underlying: Common Stock · 8,613 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. F7 · derivative.exercise_date: 100% of the shares underlying the option were fully vested as of January 16, 2019. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 02:02 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 8,613 | $17.32 | $149,138.40 |
DisclosureSEC source: 0001626199-23-000134 · wk-form4_1702432945.xml · nonDerivative · entry 5 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $17.00 to $17.56. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 02:02 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Exercise / conversionCommon Stock | 8,613 | $0.45 | $3,875.85 |
DisclosureSEC source: 0001626199-23-000134 · wk-form4_1702432945.xml · nonDerivative · entry 4 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 02:02 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 32,450 | $17.32 | $561,887.98 |
DisclosureSEC source: 0001626199-23-000134 · wk-form4_1702432945.xml · nonDerivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $17.00 to $17.56. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 02:02 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 68,870 | $17.26 | $1,189,026.78 |
DisclosureSEC source: 0001626199-23-000134 · wk-form4_1702432945.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,450 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $17.00 to $17.75. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 02:02 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 8,067 | $17.08 | $137,783.55 |
DisclosureSEC source: 0001626199-23-000134 · wk-form4_1702432945.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,320 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.00 to $17.25. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:04 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 350,000 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001626199-23-000023 · wf-form4_167296347804493.xml · derivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2033-01-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 23:03 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 215,000 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001626199-22-000024 · wf-form4_164151017636103.xml · derivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2032-01-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on the one (1)-year anniversary of January 4, 2022 (the "Vesting Commencement Date"), and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, such that 100% of the Shares subject to the Option will be vested and exercisable as of the four (4)-year anniversary of the Vesting Commencement Date, subject to Optionee continuing to be a Service Provider through each such date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 21:16 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 45,262 | $10.01 | $452,963.99 |
DisclosureSEC source: 0001626199-21-000115 · wf-form4_163225898002703.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,387 F4 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 21:16 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 400,000 | $9.40 | $3,760,000.00 |
DisclosureSEC source: 0001626199-21-000115 · wf-form4_163225898002703.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alpine ImmunoSciences, L.P. Disclosed balance after: 2,600,980 F1 · shares: These shares were sold in a private transaction to an investor in the Issuer simultaneously with the closing of the Issuer's private placement on September 17, 2021. F2 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 22:06 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 6,768 | $10.00 | $67,696.24 |
DisclosureSEC source: 0001626199-21-000109 · wf-form4_163191637248565.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,649 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 22:06 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 3,484 | $10.00 | $34,840.00 |
DisclosureSEC source: 0001626199-21-000109 · wf-form4_163191637248565.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,417 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 3,479 | $10.00 | $34,791.74 |
DisclosureSEC source: 0001626199-21-000087 · wf-form4_162500119417820.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,901 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.